HOME >> BIOLOGY >> NEWS
Cancer-Risk Analysis Program Goes Public

DALLAS - April 27, 1999 - A UT Southwestern Medical Center at Dallas physician-scientist is offering his interactive, comprehensive computer program for breast-cancer risk assessment at no charge to health professionals providing breast care.

Dr. David Euhus, assistant professor of surgical oncology, designed the user-friendly personal computer-based program called "CancerGene," which will collect a family history, draw a pedigree and display probabilities of developing breast cancer at various ages as well as probabilities of inheriting an abnormal breast-cancer-susceptibility gene. Euhus co-directs the Mary L. Brown Breast Cancer Genetics and Risk Assessment Program in the Southwestern Center for Breast Care and is the George and Carol Poston Professor in Breast Cancer Research.

Asked why there is no charge for the computer program, he said, "We're giving it away because it is useful for assisting women who are concerned about their breast-cancer risk. Does there need to be a better reason?"

The program leads breast-care providers through a structured on-screen interview that collects a detailed family history and then displays probabilities in graphs and tables. The outputs include: age-specific probability of developing breast cancer, age-specific probability of developing ovarian cancer and probability of having a BRCA1 or BRCA2 gene mutation. The program employs several models, including Duke University Institute of Statistics and Decisions Sciences' BRCAPRO.

The user also is able to see if the program can suggest another cancer syndrome applicable to the family history by simply clicking on the appropriate button. In addition, "CancerGene" has an easily accessible glossary of cancer syndromes.


'"/>

Contact: Heather Stieglitz
heather.stieglitz@email.swmed.edu
214-648-3404
UT Southwestern Medical Center
27-Apr-1999


Page: 1

Related biology news :

1. Analysis fingers causes of desertification
2. Analysis of gene expression in lymphoid cells can determine lymphoma cancer
3. Analysis of biological clock may lead to greater understanding of human disease
4. Analysis uncovers critical stretches of human genome
5. Newer methods added, scope expanded in new Methods of Soil Analysis Book
6. MelTec GmbH announces new technology for High-Throughput Topological Analysis of human cells
7. Analysis of impact studies reveals how bottom fishing affects seafloor denizens
8. Analysis of flight performance in wandering albatrosses yields insights into foraging patterns of different ages and sexes
9. Analysis of Martian meteorite using unique magnetic microscope
10. Urine Tests Will Do Better Than Pelvic Exams To Save Teens From Serious Effects Of Sexually Transmitted Diseases, UCSF Analysis Shows
11. Farmers Can Afford To Clean Up Gulf Of Mexico, Analysis Shows

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cancer Risk Analysis Program Goes Public

(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:9/2/2015)... -- Biovista Inc. is glad to announce ... science challenge, a global competition hosted by the Rare ... the latest life science innovations and technologies. ... capability to support Steven Laffoon and his ... Niemann-Pick Disease Type A (NPA), a rare and fatal ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
(Date:9/2/2015)... -- Aytu BioScience, Inc. (OTCQB: AYTU), a specialty healthcare ... conditions, announced today that it has closed the final ... raising a total of $5.175 million, which includes proceeds ... Josh Disbrow , Chief Executive Officer of ... to be used to conduct clinical studies for both ...
(Date:9/2/2015)... , September 2, 2015 ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, announced today that presentations highlighting ... will be delivered at the Ophthalmology Futures European ... Society of Cataract & Refractive Surgeons ("ESCRS"), both ...
Breaking Biology Technology:Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
Cached News: